BeiGene Collaborates with EUSA Pharma to Develop and Commercialize Sylvant (siltuximab) and Qarziba (dinutuximab beta) in Greater China

 BeiGene Collaborates with EUSA Pharma to Develop and Commercialize Sylvant (siltuximab) and Qarziba (dinutuximab beta) in Greater China

BeiGene Collaborates with EUSA Pharma to Develop and Commercialize Sylvant (siltuximab) and Qarziba (dinutuximab beta) in Greater China

Shots:

  • EUSA to receive up front, up to $160M milestones and royalties on sales of products in the licensed territories.  BeiGene to get an exclusive right to develop & commercialize Sylvant in Greater China and Qarizba in mainland China
  • BeiGene will fund and responsible for all clinical development and regulatory submissions in the territories and will launch and commercialize both the therapies following their approvals
  •  Qarziba is mAb targeting carbohydrate moiety of disialoganglioside 2 (GD2) currently approved in the EU for the treatment of high-risk neuroblastoma and while Sylvant is mAb targeting IL-6, approved in 40+ countries to treat iMCD. Both the therapies have been listed for NMPA’s FT approval in China

Click here to­ read full press release/ article | Ref: BeiGene | Image: BeiGene

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post